• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Purdue Pharma, Accused Of Fueling Opioid Crisis, Files For Chapter 11

Share:

September 24, 2019

Purdue Pharma, the maker of OxyContin, filed for Chapter 11 bankruptcy protection Sunday night, just days after striking a settlement with more than 2,000 local governments over its alleged role in creating and sustaining the deadly opioid crisis.

The filing in New York follows the Sackler family agreeing to relinquish ownership of the lucrative company. The family also agreed to provide $3 billion in cash over several years and future revenue from the sale of OxyContin to assist communities hardest hit by the opioid epidemic.

On Sunday, Purdue’s board of directors approved the settlement, which includes 24 state attorneys general who sued the company, accusing it of fueling the nationwide addiction crisis by aggressively marketing OxyContin while downplaying its potential for addiction.

Following Sunday’s bankruptcy filing, the company’s board members said the deal struck with the thousands of state and local governments will provide billions to combat the country’s opioid crisis.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“This settlement framework avoids wasting hundreds of millions of dollars and years on protracted litigation, and instead will provide billions of dollars and critical resources to communities across the country trying to cope with the opioid crisis,” said Steve Miller, chairman of Purdue’s board of directors, in a statement to NPR.

“We will continue to work with state attorneys general and other plaintiff representatives to finalize and implement this agreement as quickly as possible,” he added.

The drugmaker said the value of the settlement is about $10 billion, but more than two dozen states opposed to the deal have contested that estimate, vowing to take the Sackler family to state courts in an attempt to tap into the family’s fortune.

Date: September 24, 2019

Source:

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Caira Surgical Secures $5M for Robotic Solutions for Joint Replacement SurgeryCaira Surgical Secures $5M for Robotic Solutions for Joint Replacement Surgery
  • Analysis of Regional Opportunities Awaiting for Manufacturers in 3D Printed Medical Implants MarketAnalysis of Regional Opportunities Awaiting for Manufacturers in 3D Printed Medical Implants Market
  • Acadia Professional, LLC Acquires Toro Risk Consulting Group, LLCAcadia Professional, LLC Acquires Toro Risk Consulting Group, LLC
  • iAnthus and MPX Bioceutical Announce Transformational Combination, Expands U.S. Footprint to 10 StatesiAnthus and MPX Bioceutical Announce Transformational Combination, Expands U.S. Footprint to 10 States
  • Pharmaceutical Market Boosting the Growth Worldwide: Pharmaceutical Market Dynamics and Trends, Efficiencies Forecast 2026Pharmaceutical Market Boosting the Growth Worldwide: Pharmaceutical Market Dynamics and Trends, Efficiencies Forecast 2026
  • EU Antitrust Regulators Clear Pfizer’s $43B Acquisition of SeagenEU Antitrust Regulators Clear Pfizer’s $43B Acquisition of Seagen
  • AVROBIO and Tectonic Therapeutic Announce MergerAVROBIO and Tectonic Therapeutic Announce Merger
  • Welltok Adds Four New Digital Programs, Atrium Health Adopts Butterfly’s Handheld Ultrasound and More Digital Health DealsWelltok Adds Four New Digital Programs, Atrium Health Adopts Butterfly’s Handheld Ultrasound and More Digital Health Deals

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications